I have covered AcelRx Pharmaceuticals ( ACRX ) previously, so investors should view this as an update to my earlier article on the company. In this article I will focus on the prospects of DSUVIA and Zalviso as a product – I believe the market potential is still underestimated...

REDWOOD CITY, Calif. , Nov. 13, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a publication analyzing p...

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Buy rating and $125 (15% upside) price target at SunTrust. More news on: Alexion Pharmaceuticals, Inc., Amgen Inc., Arcus Biosciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...